Legal & General Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,370
| Closed | -$25K | – | 3534 |
|
|
2020
Q4 | $25K | Hold |
1,370
| – | – | ﹤0.01% | 3011 |
|
|
2020
Q3 | $25K | Sell |
1,370
-506
| -27% | -$8.51K | ﹤0.01% | 2920 |
|
|
2020
Q2 | $28K | Sell |
1,876
-68
| -3% | -$971 | ﹤0.01% | 2930 |
|
|
2020
Q1 | $30K | Sell |
1,944
-685
| -26% | -$11.1K | ﹤0.01% | 2769 |
|
|
2019
Q4 | $43K | Buy |
2,629
+351
| +15% | +$5.85K | ﹤0.01% | 2872 |
|
|
2019
Q3 | $34K | Hold |
2,278
| – | – | ﹤0.01% | 2910 |
|
|
2019
Q2 | $34K | Buy |
2,278
+550
| +32% | +$8.98K | ﹤0.01% | 2957 |
|
|
2019
Q1 | $30K | Hold |
1,728
| – | – | ﹤0.01% | 2935 |
|
|
2018
Q4 | $31K | Hold |
1,728
| – | – | ﹤0.01% | 2898 |
|
|
2018
Q3 | $31K | Hold |
1,728
| – | – | ﹤0.01% | 3014 |
|
|
2018
Q2 | $34K | Buy |
+1,728
| New | +$32.4K | ﹤0.01% | 2961 |
|
|
2017
Q2 | – | Sell |
-3,076
| Closed | -$37K | – | 3409 |
|
|
2017
Q1 | $37K | Sell |
3,076
-1,000
| -25% | -$12.1K | ﹤0.01% | 2929 |
|
|
2016
Q4 | $54K | Buy |
4,076
+1,884
| +86% | +$25.2K | ﹤0.01% | 2872 |
|
|
2016
Q3 | $31K | Hold |
2,192
| – | – | ﹤0.01% | 2724 |
|
|
2016
Q2 | $25K | Buy |
+2,192
| New | +$35.2K | ﹤0.01% | 2804 |
|
Legal & General Group's CBMG Position: Q1 2021 in Review
Legal & General Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 1,370 shares — an estimated $25K sold.
Legal & General Group first reported a position in CBMG in Q2 2016 and held it in 15 quarters. The position peaked at $54K in Q4 2016. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Legal & General Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Legal & General Group sold 1,370 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $25K.
- Legal & General Group first reported a position in Cellular Biomedicine Group, Inc. in Q2 2016 and held it in 15 quarters.
- Legal & General Group's Cellular Biomedicine Group, Inc. position peaked at $54K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Legal & General Group's 13F filing for Q1 2021, filed 17 May 2021.